ClinicalTrials.gg
RecruitingNCT06227754FRAME-AMI3Updated May 8, 2026

OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts

An interventional study of Angiography-guided PCI group and Optical coherence tomography-guided PCI group in ST Elevation Myocardial Infarction and Myocardial Infarction, sponsored by Chonnam National University Hospital. Recruiting at 18 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Chonnam National University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,500
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of — 8 open to participants now, 12 under way, 2 of them phase 3. ST Elevation Myocardial Infarction · Korea, Republic of.

Planned enrollment
5th of 28
1,500 · median 314
Started
2024
with 1 other
No phase
14 of 36
5 open now
Primary completion
2031-03
later than 9 of 11 live
Registered
30th of 36
by date
Lead sponsor
3 of 36
Chonnam National University Hospital

Among the 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of, this one is the 5th largest by planned enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2024, is one of 14 with no phase, reaches primary completion later than 9 of the 11 other live ones, and was the 30th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

8 of the 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The aim of the study is to compare clinical outcomes between optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI).

Read the detailed description

Percutaneous coronary intervention (PCI) is a standard treatment for significantly stenotic lesion of coronary arteries, especially in the setting of acute myocardial infarction (AMI) where timely reperfusion is important. Traditionally, visual assessment by coronary angiography has been the main tool to identify coronary artery disease and guide revascularization. However, it is known that angiography alone is unable to adequately evaluate significance of stenotic lesion or optimization status of the stent, and that angiography suffers from high intra- and interobserver variability. Thus, methods for intracoronary imaging and/or physiology have been developed to aid these limitations.

During the PCI procedure, intravascular imaging devices such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are useful tools for providing information on lesion characteristics and optimal stent implantation with regard to appropriate reference segment, stent expansion, stent apposition, and possible acute complications. Therefore, intravascular imaging guidance may improve clinical outcomes after complex PCI. However, although previous randomized controlled trial and registries showed significantly lower rates of major adverse clinical events following IVUS-guided PCI compared with angiography-guided PCI, the randomized controlled trials were limited with small sample size and dealt with very selected lesion subsets such as chronic total occlusion (CTO) or long lesions. Moreover, although some studies observed similar clinical outcomes between IVUS-guided PCI and OCT-guided PCI, it is uncertain whether OCT-guided PCI improves clinical outcomes compared with angiography-guided PCI.

Currently, randomized controlled trial to support beneficial impact of OCT-guided PCI, especially in patients with acute myocardial infarction (AMI) is lacking. One randomized clinical trial in 2016 with 240 non-ST-elevation myocardial infarction patients have reported higher postprocedural fractional flow reserve and similar incidence of major adverse cardiac events with the use of OCT compared to angiography alone, but this study mostly focused on immediate physiologic findings of OCT-guided PCI and only demonstrated clinical outcomes on short-term follow-up. Although the ILUMIEN IV trial evaluated efficacy of OCT-guided PCI among high risk patients including lesions were considered to be responsible for a recent myocardial infarction, there was no apparent difference in the target-vessel failure at 2 years. There is no randomized controlled trial that can provide information on its long-term clinical impact, and current clinical guidelines puts OCT on Class 2a recommendation as an alternative for IVUS, with the exception of ostial left main disease.

In this regard, randomized controlled trial comparing clinical outcome following PCI in patients with AMI where procedural optimization is performed under OCT-guidance or angiography alone would provide valuable evidence to enhance prognosis after treatment of AMI. Therefore, FRAME-AMI 3 trial has been designed to compare clinical outcomes after PCI for infarct-related artery using either OCT-guided or angiography-guided strategy.

03

Conditions studied

  • ST Elevation Myocardial Infarction
  • Myocardial Infarction

Keywords

  • ST-segment elevation MI
  • Optical coherence tomography
  • Intravascular imaging
  • Primary PCI
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be at least 19 years of age
  • Acute ST-segment elevation myocardial infarction (STEMI)

    *STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block1

  • Primary percutaneous coronary intervention (PCI) in \< 12 h after the onset of symptoms for STEMI patients
  • Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he/she or his/her legally authorized representative provides written prior to any study related procedure.

Exclusion criteria

Exclusion Criteria:

  • Target lesions not amenable for PCI by operators' decision
  • Ostial lesions located in left main vessel or right coronary artery (left main body or distal bifurcation lesions can be enrolled by operator's discretion)
  • ≤30 ml/min/1.73 m2 and not on dialysis (chronic dialysis dependent patients are eligible for enrolment regardless of creatinine clearance)
  • Cardiogenic shock (Killip class IV) at presentation
  • Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus
  • Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)
  • Pregnancy or breast feeding
  • Non-cardiac co-morbid conditions are present with \<2 year or that may result in protocol non-compliance (per site investigator's medical judgment)
  • Unwillingness or inability to comply with the procedures described in this protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,500 participants (estimated)

Study arms

  • Active comparator
    Angiography-guided PCI

    The PCI procedure in this group will be performed as standard procedure.

    Procedure: Angiography-guided PCI group

  • Experimental
    Optical coherence tomography-guided PCI

    Use of OCT will be allowed at any step of PCI (pre-PCI, during PCI and post-PCI), but OCT after stent implantation will be mandatory. In this group, the recommendations for selecting reference segment, selecting appropriate size of stent, and stent optimization are as follows. OPTIS imaging catheter (Abbott Vascular) will be used for the imaging arm according to MLD MAX algorithm.

    Procedure: Optical coherence tomography-guided PCI group

Interventions

  • ProcedureAngiography-guided PCI group

    The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 10% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended.

  • ProcedureOptical coherence tomography-guided PCI group

    \[Stent Optimization\] 1. Stent Expansion: Visually assess residual angiographic diameter stenosis \<10% "AND" ① In non-LM lesions: In-stent minimal lumen area (MSA) \>80% of the average reference lumen area "OR" \>4.5 mm2 ② In LM lesion: MSA\>7 mm2 for distal LM and \>8 mm2 for proximal LM 2. Stent Apposition: No major malapposition (defined as a distance from stent strut to adjacent intima ≥400 um and \< 1mm length) of the stent over its entire length against the vessel wall 3. Edge Dissection: No major edge dissection in the proximal or distal reference segments, defined as 5 mm from the edge of the stent, extended to media layer with potential to provoke flow disturbances (defined as \>60° of the circumference of the vessel at site of dissection and/or \>2 mm in length of dissection flap)

06

What researchers measure

Primary outcomes

  1. Target vessel failure

    a composite of cardiac death, target-vessel myocardial infarction, clinically-driven target-vessel repeat revascularization, definite or probable stent thrombosis

    Time frame: 2 years after last patient enrollment

Secondary outcomes

  1. All-cause death

    All-cause death

    Time frame: 2 years after last patient enrollment

  2. Cardiac death

    Cardiac death

    Time frame: 2 years after last patient enrollment

  3. Rate of any myocardial infarction

    Any myocardial infarction, defined by Forth Universal definition of myocardial infarction

    Time frame: 2 years after last patient enrollment

  4. Rate of spontaneous myocardial infarction

    Spontaneous myocardial infarction, defined by Forth Universal definition of myocardial infarction

    Time frame: 2 years after last patient enrollment

  5. Rate of procedure-related myocardial infarction

    Procedure-related myocardial infarction, defined by ARC II definition

    Time frame: 2 years after last patient enrollment

  6. Rate of any revascularization

    Any revascularization (clinically-driven or ischemia-driven)

    Time frame: 2 years after last patient enrollment

  7. Rate of target vessel revascularization

    Target vessel revascularization

    Time frame: 2 years after last patient enrollment

  8. Rate of stent thrombosis

    Definite or probable stent thrombosis, defined by ARC II definition

    Time frame: 2 years after last patient enrollment

  9. Total procedural time

    Total procedural time (primary PCI to end of the procedure including amount of staged procedure)

    Time frame: at least 1 week after index procedure

  10. Total fluoroscopy time

    Total fluoroscopy time (primary PCI to end of the procedure including amount of staged procedure)

    Time frame: at least 1 week after index procedure

  11. Total amount of contrast use

    Total amount of contrast use (primary PCI to end of the procedure including amount of staged procedure)

    Time frame: at least 1 week after index procedure

  12. Incidence of contrast-induced nephropathy

    Incidence of contrast-induced nephropathy, defined as an increase in serum creatinine of ≥0.5mg/dL or ≥25% from baseline within 48-72 hours after contrast agent exposure.

    Time frame: at least 1 week after index procedure

07

Study locations

18 of 18 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — After publication of main paper, de-identified data will be shared upon reasonable requests after discussion by Executive Committee.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After publication of main paper.

Access criteria: Executive Committee will discuss to share the de-identified data upon reasonable requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Mar 2031, 84 months after the start.

Of 135 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 84 months is above that.

Counting every sponsor, half of 145 studies reached it within 40 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2023
First posted
Jan 29, 2024
StartActual
Mar 25, 2024
Primary completionEst.
Mar 31, 2031
CompletionEst.
Dec 31, 2031
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06227754
Lead sponsor
Chonnam National University Hospital
Responsible party
Young Joon Hong (Professor, Chonnam National University Hospital) — Principal investigator
First posted
Jan 29, 2024
Start date
Mar 25, 2024
Primary completion
Mar 31, 2031 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
May 8, 2026

Study contacts

Seung Hun Lee, MD, PhD
Contact
lsh8602@naver.com
82-2-220-6246
Young Joon Hong, MD, PhD
Contact
hyj200@hanmail.net
82-2-220-5778
Young Joon Hong, MD, PhD
principal investigator · Chonnam National University
Joo-Yong Hahn, MD, PhD
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion